Astrazeneca Ab

Astra Zeneca U.k. Limited

Astra Pharmaceuticals Limited

Paul Andrew Willis

Brian Springthorpe

Anthony Howard Ingall

Roger Victor Bonnert

Simon David Guile

David Hardern

Michael P Mortimore

Mark Furber

Lilian Alcaraz

Philip Vellacott Thorne

Austen Pimm

Fraser Hunt

Barrie Martin

Simon Fraser Hunt

Iain Alistair Stewart Walters

Stephen Thom

Iain Walters

Timothy Jon Luker

Andrew Baxter

Garry Pairaudeau

Bryan Glyn Roberts

Piotr Antoni Raubo

Richard Evans

David Cox

Rhonan Lee Ford

Peter Cage

Moya Caffrey

Stephen Anthony St-Gallay

Elizabeth Kinchin

Toby Thompson

Roger Brown

David Hardem

Christine Eyssade

Matthew Hallam

Rupert Austin

Triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows: wherein R, X and Rthrough Rare as defined in the specification.

Triazolo(4,5-D)pyrimidine compounds

The invention provides certain thiazolopyrimidine compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Thiazolo (4,5-D) pyrimidine compounds

The present invention relates to isoquinolinone derivatives of formula (I): wherein R, R, R, R, R, Rand Rare as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Compounds and their uses 707

The invention provides compounds of formula (IA), processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. 

[object Object]

The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.

Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition

The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CHor CHCH, E represents C(O)NH or NHC(O) and Rrepresents a group of formula (I). 

Adamantane derivatives

Compounds

The invention provides certain heterocyclic compounds, processes, and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy; in formula (I), A is a group of formula (a) or (b).

Pyrimidine compounds and their use as modulators of chemokine receptor activity

The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CHor CHCH, E represents C(O)NH or NHC(O) and Rrepresents a group of formula (I).

The invention provides certain thiazolopyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

The invention provides certain thiazolopyrimidine compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof; processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Thiazolo(4,5-d)pyrimidine compounds

Triazolo(4,5-d)pyrimidine compounds

The invention relates to triazolo&lsqb;4,5-d&rsqb;pyrimidin-3-yl derivatives which are useful in the treatment of platelet aggregation disorders.

Triazolo&lsqb;4,5-D&rsqb;pyrimidinyl derivatives and their use as medicaments

Compounds of formula having the following stereochemistry

1,2,3-triazolo&lsqb;4,5-d&rsqb;pyrimidines as P2T receptor antagonists

Growing community of inventors

Loughborough, United Kingdom

Paul Andrew Willis